From the Editor

May 04, 2016
Pharmaceutical Executive
The Boston biotech cluster proved an ideal setting for Pharm Exec's recent annual Editorial Advisory Board meeting. William Looney reports.
Apr 01, 2016
Pharmaceutical Executive
The challenges facing the ad industry and big Pharma are remarkably similar—a point driven home by four distinct themes discussed at this year's 4A's Transformation conference.
Mar 07, 2016
Pharmaceutical Executive
With the emerging industry commitment to publicly disclose research and clinical trial results, two pivotal issues come to mind, writes William Looney.
Feb 05, 2016
Pharmaceutical Executive
William Looney identifies three areas where the insular, often maladroit tone of the industry-investor dialogue may be morphing to something more grounded in the larger societal context of healthcare.
Jan 20, 2016
Pharmaceutical Executive
Pharm Exec Editor-in-Chief William Looney offers his take on the opportunities, threats, and other big issues facing the industry in the new year.
Dec 07, 2015
Pharmaceutical Executive
A new discipline—population health—contests disease treatment as an end in itself. It asks: besides advancing the science of medicine, what do biopharmaceuticals actually do to improve health overall?
Nov 16, 2015
Pharmaceutical Executive
Building on our annual look at the industry's product pipeline, four key themes stand out that are driving the fast-changing environment for drug development, writes William Looney.
Oct 08, 2015
Pharmaceutical Executive
A new and more compelling strategy must be crafted to engage critics on drug pricing and bolster biopharmaceuticals as a leader in technological innovations that lower health costs overall. William Looney reports.
Sep 08, 2015
Pharmaceutical Executive
A closer look at this year's Industry Audit numbers hints to a clear divide between two alternative strategies for long-term growth: scale versus focus. William Looney comments.
Aug 13, 2015
Pharmaceutical Executive
The big data revolution offers great promise for drug development versus the traditional ways of bringing medicines to market, but there is a larger issue at stake: how to turn data quantity into data quality. William Looney reports.
табак для кальяна цена
lorem ipsum